Dupixent
Atopic dermatitis
Key Facts
About Sanofi
Sanofi is one of the world's largest pharmaceutical companies, leveraging artificial intelligence and deep immunology expertise to develop breakthrough treatments and vaccines. With a comprehensive pipeline spanning multiple therapeutic areas and a strong commercial portfolio of established medicines, the company is committed to improving global health outcomes. Their recent focus on AI-powered drug discovery and development positions them at the forefront of pharmaceutical innovation.
View full company profileAbout Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a premier biotechnology company founded in 1988 and headquartered in Tarrytown, New York. The company has built a diversified portfolio of FDA-approved treatments and maintains a robust pipeline across oncology, immunology, ophthalmology, and other therapeutic areas. Regeneron's proprietary VelociSuite technologies, including VelocImmune mice and advanced manufacturing capabilities, enable rapid drug discovery and development. With multiple billion-dollar commercial products and strong financial performance, Regeneron ranks among the most successful biotech companies globally.
View full company profileAbout Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a premier biotechnology company founded in 1988 and headquartered in Tarrytown, New York. The company has built a diversified portfolio of FDA-approved treatments and maintains a robust pipeline across oncology, immunology, ophthalmology, and other therapeutic areas. Regeneron's proprietary VelociSuite technologies, including VelocImmune mice and advanced manufacturing capabilities, enable rapid drug discovery and development. With multiple billion-dollar commercial products and strong financial performance, Regeneron ranks among the most successful biotech companies globally.
View full company profileTherapeutic Areas
Other Atopic dermatitis Drugs
| Drug | Company | Phase |
|---|---|---|
| Lebrikizumab | Eli Lilly | Phase 3 |
| ASP2408 | Astellas Pharma | Phase 2 |
| KW-6356 | Kyowa Kirin | Phase 2 |
| KHK4083 | Kyowa Kirin | Phase 2 |
| Opzelura (ruxolitinib cream) | Ono Pharmaceutical | Approved |
| ONO-7913 | Ono Pharmaceutical | Phase 2 |
| KT-474 | Kymera Therapeutics | Phase 2 |
| GRC 27864 | Glenmark Pharmaceuticals | Phase 2 |
| ARQ-234 | Arcutis Biotherapeutics | Preclinical/Phase 1 |
| STAR-0310 | BioCryst Pharmaceuticals | Phase 1 |
| Rezpegaldesleukin | Nektar Therapeutics | Phase 2b |
| ZL-1503 | Zai Lab | Phase (Early Clinical) |